Stock Analysts’ upgrades for Tuesday, May 24th: Caladrius Biosciences (NASDAQ:CLBS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $0.50 target price on the stock. According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and […]
/PRNewswire/ The "T-Cell Therapy Market Research Report by Modality, by Therapy Type, by Indication, by Region - Global Forecast to 2026 - Cumulative Impact.
/PRNewswire/ The "T-Cell Therapy Market Research Report by Modality, by Therapy Type, by Indication, by Region - Global Forecast to 2026 - Cumulative Impact.
Biotechs With Massive Upside [BioCryst Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., AbbVie Inc]
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with
The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.
The Life Sciences Report: Vernon, up to 30 thousand (30K) people currently have a vital and pressing need for experimental therapeutic and immunization agents to protect them from the ongoing Ebola virus disease (EVD) outbreak in West Africa. That 30K is a conservative estimate, according to University of Oxford epidemiologist Oliver Brady, who wrote an op-ed piece for the World View column of
The Umbilical Cord Blood Banking Market To Witness A Healthy Facelift Between 2020 comunicati.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comunicati.net Daily Mail and Mail on Sunday newspapers.